Inanovate

On-the-spot diagnosis for prostate cancer patients
Friday 23 April 2010

Inanovate, one of the spin-off companies from the EPSRC-funded Nanoscale Physics Research Laboratory (NPRL) at the University of Birmingham, has developed a nanoscale device which can diagnose prostate cancer with more accuracy than current tests. Read more at the EPSRC web site.